Health
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
OSAKA, Japan & CAMBRIDGE, Mass., May 04, 2026--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/728949aaca3be5364b420dbd9cdc8f18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vazwzH6U1K5a15Zu2eG3Ng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMg--/https://media.zenfs.com/en/business-wire.com/728949aaca3be5364b420dbd9cdc8f18","width":480,"height":266}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients","length":139,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":139,"olType":false},{"type":"text","content":"OSAKA, Japan & CAMBRIDGE, Mass., May 04, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duration while maintaining flexible, up to once-monthly dosing for patients (every three or four weeks for PID).","length":1033,"tagName":"p"},{"type":"text","content":"The TAK-881-3001 clinical trial evaluated the PK, efficacy, safety, tolerability and immunogenicity of TAK-881 in adults and pediatric patients aged 2 years and older with PID previously treated with IG therapy and compared them with HYQVIA in patients aged 16 years and older. Initial topline data show TAK-881:","length":312,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Achieved comparable PK: The study met its primary endpoint demonstrating eq...